Drug Trial Radar · NCT05347849
Single Ascending Dose Study With BPL-003 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Feb 14, 2022
Primary completion
Jan 19, 2024
Study completion Jan 19, 2024
Sponsor
- Lead sponsor
- Beckley Psytech LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will evaluate safety, tolerability and PK profile of BPL-003 in healthy subjects
Conditions
- Pharmacokinetics in Healthy Adults
Interventions
BPL-003Drug
A single dose of BPL-003 will be administered intranasally
PlaceboOther
A single dose of placebo will be administered intranasally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with treatment emergent AEs (TEAES)Time frame: From screening through to the follow up visit, up to 65 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Medicines Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.